Saladax Biomedical’s MyCare line of blood tests allow for cancer patients to receive personalized doses of chemotherapy when undergoing treatment. MyCare tests provide oncologists with data for pharmacokinetic (PK)-guided drug dose adjustment, enabling optimized cancer treatment efficacy and a reduction in the risk of severe toxic side effects associated with chemotherapy for each individual patient.
Three MyCare assays – My5-FU™, MyPaclitaxel™, and MyDocetaxel™ are currently offered to oncologists in various countries (see Our Global Distribution Partners for information on availability in your country). These are the first assays in the Saladax portfolio of 15 MyCare assays in various stages of development – 13 in the field of oncology and two addressing Central Nervous System (CNS) disorders.
FOR ADDITIONAL INFORMATION ON MyCare, PLEASE CONTACT:
Sr. VP & Chief Commercial Officer
Saladax Biomedical, Inc.
116 Research Drive
Bethlehem, PA 18015
Phone: (610) 419-6731 x26524
Fax: (610) 849-5001